J&J’s Carvykti and BMS’ Abecma Win FDA Approvals for Earlier Use in Multiple Myeloma
XTalks
APRIL 11, 2024
J&J’s Carvykti vs. BMS’ Abecma: Continuing Face Off as Market Rivals Carvykti’s expanded second-line approval gives it a one-line edge over Abecma’s third-line nod. J&J has ambitious plans for Carvykti as it is looking to target peak product sales of over $5 billion for the therapy.
52 
Let's personalize your content